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ABSTRACT 
Paradoxical exacerbation of the signs and symptoms of tuberculosis may occur not only after 
antituberculosis therapy, but also soon after the initiation of a potent combination of 
antiretroviral drugs in human immunodeficiency virus (HIV) serpositive patients with 
tuberculosis. We report a case of immune reconstitution syndrome in response to antiretroviral 
therapy in a HIV-positive patient on antituberculosis therapy for multidrug-resistant 
tuberculosis. 
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INTRODUCTION 
The introduction of highly active 
antiretroviral therapy (HAART) for the 
treatment of human immunodeficiency virus 
(HIV) infection has resulted in a dramatic 
decline in HIV related morbidity and mortality. 
This decline is mainly due to a drop in the 
incidence of diseases caused by opportunistic 
pathogens1. These changes in natural history of 
HIV infection seem to occur when HIV 
replication is brought under control. This in turn 
allows pathogen specific immune responses to 
be maintained or restored2, leading to an 
inflammatory response. This exaggerated 
inflammatory response to an opportunistic 
pathogen, in HIV infected patients is known as 
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immune reconstitution syndrome (IRS). This is 
similar to the paradoxical reaction, described in 
tuberculosis (TB) patients in the pre-AIDS era, 
characterised by worsening of the signs and 
symptoms of tuberculosis, but associated with 
negative culture and attributed to improved 
immune responsiveness. In HIV infected 
patients, IRS has been most commonly 
described in patients with TB lymphadenitis, 
Mycobacterium avium complex, Cytomegalo- 
virus (CMV)3 or Cryptococcus neoformans4 
infections. 
We report a case of IRS after initiation of 
antiretroviral therapy (ART) in a patient 
receiving antituberculosis therapy (ATT), for 
multidrug-resistant tuberculosis (MDR-TB). 
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CASE REPORT 
A 28-year-old lady presented to the HIV clinic 
of Tuberculosis Research Centre, in September 
2003, with complaints of dry cough, intermittent 
headache, and weight loss of greater than six 
kilograms over a nine-month period. Her 
husband had died of AIDS and TB, seven years 
ago; treatment details of which were not 
available. She was known to be HIV-positive but 
in apparently good health till she developed 
these complaints. There was no previous history 
of treatment for tuberculosis. 
She weighed 65.0 kg and was in good general 
condition. Bacille Calmette-Guerin (BCG) scar 
was absent. Respiratory system examination 
revealed scattered crepitations in the right 
mammary and infra-axillary areas. Her haema- 
tology and blood biochemistry results were 
within normal limits. She was asked to provide 
three-overnight/early morning specimen of 
sputum for bacteriologcal examination. Sputum 
smears were negative for acid-fast bacilli (AFB). 
Chest radiograph (Figure 1) showed prominent 
bronchovascular markings. Mantoux test with 
1 TU was 2.5 mm at 48 hours. Her plasma HIV 
viral load was 72,500 copies/ml, (Roche Cobas 
Amplicor automated viral load monitor). CD4+ 
T cell percentage was measured by flow 
cytometry (Coulter Epics Altra) using a three- 
colour panel of monoclonal antibodies (CD3/ 
CD4/CD8). CD4+ T cell count was calculated by 
multiplying the CD4% with absolute 
lymphocyte count. Her CD4+ T- cell count was 
90 cells/mm3. Contrast enhanced computed 
tomographic scan (CECT-scan) of the chest 
(Figure 2) showed evidence of focal areas of 
fibrosis, reticulonodular lesions in the posterior 
basal segments of both lungs, more on the left 
side. There was also evidence of fibrous strands 
in the right middle lobe (Figure 2). In view of 
the clinical and radiological abnormality, she 
was started on antituberculosis therapy (ATT) 
with Revised National Tuberculosis Control 
Programme (RNTCP) category I treatment using 
(thrice weekly regimen of ethambutol (1200 
mg), isoniazid (600 mg), rifampicin (600 mg) 
and pyrazinamide (1500 mg) and 10 mg of 
pyridoxine along with one tablet of 
cotrimoxazole DS (double strength) daily. Pre- 
treatment sputum cultures were negative for 
Mycobactenurn tuberculosis. 
Soon after starting ATT, patient complained 
of servere itching all over her body, especially 
on the days she consumed ATT. By drug 
Figure 1. Chest radiograph (PA view) showing 
prominent bronchovascular markings. 
Figure 2. CT scan of the chest showing focal areas of 
fibrosis, reticulonodular lesions in posterior basal 
segments of both lungs. 
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exclusion strategy, the offending agent was 
identified as pyrazinamide and it was 
withdrawn as she did not respond to 
symptomatic management. Patient began to 
improve symptomatically. She was supplied 
drugs once a week as she was working and 
direct observation of treatment was not done. In 
November 2003, her sputum smears became 
positive and culture grew M. tuberculosis. 
Sensitivity tests were set up then. 
By January 2004, patient developed 
productive cough, evening rise of temperature 
and weight loss of two kilograms. Her chest 
radiograph (Figure 3) showed signs of 
deterioration with a parenchymal opacity along 
the right horizontal fissure. In the next few 
weeks, sensitivity reports became available, that 
showed a resistance pattern to all the four first 
line antituberculosis drugs, namely ethambutol, 
isoniazid, rifampicin and streptomycin. 
Pyrazinamide sensitivity was not done. She 
was diagnosed to have multidrug-resistant 
tuberculosis (MDR-TB) and was started on 
kanamycin (1.0 gm), thrice weekly along with 
daily ofloxacin (600 mg), ethambutol (800 mg), 
cycloserine (500 mg) and ethionamide (500 mg). 
By late February 2004, her CD4+ cell counts 
dropped to 65 cells/mm3 and her body weight 
was 63.0 kilograms. In view of continuous 
vomiting induced by ethionamide, this drug 
had to be withdrawn and she continued with 
the rest of the drugs without any complaints. At 
the same time, she was also started on triple 
drug regimen of antiretroviral therapy (ART) 
with stavudine (40 mg), lamivudine (150 mg) 
and nevirapine (200 mg) all given twice daily, 
after the initial dose escalation for nevirapine. 
Patient started showing sings of clinical impro- 
vement. 
Three weeks after the initiation of ART, the 
patient developed continuous high-grade fever, 
breathlessness and productive cough. On 
examination, she was dehydrated, toxic, and on 
auscultation of chest, coarse crepitations were 
heard all over the right lung. She was hospita- 
lised in a private institution and managed 
symptomatically with intravenous fluids, 
broad-spectrum antibiotics and antipyretics. 
Patient continued to have high-grade fever. 
sputum culture for fungal and bacterial 
pathogens, blood Widal and urine culture were 
done. Peripheral smears for malarial and filarial 
parasites were negative. Chest radiograph 
showed right upper zone and middle zone 
consolidation, worse than the previous chest 
radiograph, that was obtained a month ago 
(Figure 4). Out of the six sputum specimens 
collected, only one smear was positive for AFB. 
Her haemoglobin was 9.2 gm% with a CD4+ cell 
count of 114 cells/mm3. 
Rapid tests for hepatitis B and C, tests for 
antibodies to CMV and toxoplasma were 
negative. Her blood culture and urine culture 
did not show any growth. Hence, a diagnosis of 
IRS was considered and paracetamol was 
administered. Patient continued to have fever 
and cough. She was also losing weight and by 
the end of March 2004 she was only 52.0 
kilograms. She became very depressed and 
~ 
Figure 3. Chest radiograph (PA view) showing signs 
of linear parenchymal opacity along the right 
horizontal fissure. withdrawn. 
Again a complete blood count, liver function 
and renal function tests, chest radiography, 
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Figure 4. Chest radiograph (PA view) showing 
increasing consolidation of right upper and middle 
lobes. 
In view of her worsening clinical condition 
and with the working diagnosis of IRS, she was 
started on daily oral prednisolone (1 mg/kg 
bodyweight) and was monitored closely. Within 
a week of starting oral corticosteroids, patient 
started showing signs of improvement. Her 
fever subsided; her oral intake increased and 
she became more cheerful. After 10 days at this 
dosage, oral prednisolone was tapered at the 
rate of 5 mg per week over a period of two 
months. Meanwhile she continued to receive 
ART and drugs for the treatment of MDR-TB. 
Chest radiograph repeated after one month, 
showed regression of lesions in right upper and 
middle lobes (Figure 5). There was no evidence 
of any new pulmonary lesion. She began 
gaining weight (59.0 kg) as well as self- 
confidence. Twelve weeks after starting ART, 
her viral load was below 400 copies/ml and her 
CD4+ count rose to 204 cells/mm3. 
DISCUSSION 
We have described a patient with MDR-TB 
Figure 5. Chest radiograph (PAview) showing signs 
of regressing lesion in the right upper and middle 
lobe. There is no evidence of any fresh pulmonary 
lesions. 
and immunosuppression due to HIV, who 
developed exacerbation of her TB symptoms 
along with deterioration of her chest 
radiograph, soon after the initiation of potent 
antiretroviral therapy. Narita and colleagues5 
have reported that “paradoxical response” 
occurs in 36% of patients with HIV-TB co- 
infection after the initiation of HAART. An 
event rate of 30-40% has also been estimated in 
patients who start treatment with low (ie., <100 
cells/µl) CD4+ counts6. The most common 
clinical manifestations include hectic fever, 
intrathoracic and cervical lymphadenopathy 
and like in our case, worsening of chest 
radiographic appearance of tuberculosis. Our 
patient was quite toxic and ill looking from the 
beginning of her IRS unlike general reports that 
patients with IRS are not toxic and subjectively 
refer to as feeling well. 
Extensive work-up is required to rule out the 
presence of condition other than TB as the cause 
of fever, before making a diagnosis of IRS in 
these patients. These inlcude looking for the 
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presence of other opportunistic pathogens, like 
cytomegalovirus, toxoplasma salmonella, non- 
tuberculous mycobacteria and other organisms. 
Our patient was repeatedly tested for AFB in 
sputum during her febrile episodes and they 
were negative at all occasions except once. In a 
case of IRS with worsening respiratory 
symptoms, evidence of increasing M. 
tuberculosis replication is usually lacking. Chest 
radiographic appearances can vary from new 
pulmonary infiltrates, pleural effusion, miliary 
infiltrates or worsening of the original 
Delayed type hypersensitivity response to 
tuberculin usually appears where it was absent 
before starting HAART. This also indicates 
HAART'S restoration of anti M. tuberculosis cell 
mediated immune response7. Paradoxical 
reactions have been attributed to immunologic 
causes such as the strengthening of the host's 
delayed hypersensitivity response or a decrease 
in suppressor mechanisms8. Like in our patient, 
the TB signs and symptoms may worsen after 
initiation of ART. 
Our patient had a very low CD4+ cell count 
at the initiation of ATT and ART. Generally, 
paradoxical responses occur in patients with a 
CD4+ T-cell count of less than 100 cells/µl 
before the initiation of HAART, which increases 
significantly after HAART is underway9. One 
study10 showed that immune reconstitution 
events start at a median time from the start of 
antiretroviral therapy of 22.5 days. 
Inflammation associated with restoration of 
anti M. tuberculosis cell mediated immunity after 
commencing HAART is usually controlled by 
the use of anti-inflammatory therapy, including 
corticosteroids. Our patient responded to oral 
prednisolone treatment. Her antiretroviral 
therapy and antituberculosis treatment were 
continued uninterrupted throughout her period 
of immune restoration. The general treatment 
strategy of IRS includes continuation of ARV 
therapy, addition of antimicrobial therapy to 
suppress the replication of related pathogens 
and anti-inflammatory therapy. Rarely, if this 
approach fails, ARV therapy may have to be 
discontinued at least temporarily. 
tuberculous lesions5. 
The main reason for reporting this case is the 
diagnistic dilemma faced when patients on ARV 
and TB treatment develop clinical deterioration. 
What are the likely causes of these abnorma- 
lities, when no demonstrable pathogens are 
identified? Should corticosteroids be started for 
patients on TB treatment ? Should the ARV be 
withdrawn? The timing, clinical manifestations 
and radiographic changes in the present case 
suggested that all the clinical events were due to 
the immunologic changes associated with 
successful ART. This case demonstrates that 
AIDS associated TB including MDR-TB can 
worsen during the initial weeks of successful 
chemotherapy and can also flare up, sometimes 
at new sites. Treatment failure, drug fever and 
the development of non-TB HIV-related 
conditions were considered unlikely here since 
an extensive infectious work-up was negative 
and the clinical symptoms and lesions subsided 
despite continuation of the same TB treatment. 
Use of short-term corticosteroid treatment (46 
weeks) that suppresses the enhanced immune 
response, while maintaining patient on 
appropriate ATT and antiretroviral therapy 
proved to be helpful, even in a case of MDR-TB. 
In summary, a paradoxical exacerbation of 
signs and symptoms of tuberculosis may occur 
not only after ATT, but more commonly, soon 
after the initiation of potent combination of ART 
in HIV infected TB patients. A thorough 
investigation is necessary to exclude other 
aetiological causes before a diagnosis of 
immune reconstitution can be made. It is 
important that treating clinicians be aware of 
this phenomenon and realise that this simply 
represents an enhanced immune response to M. 
tuberculosis antigens following potent combina- 
tion antiretroviral therapy and not treatment 
failure, drug reaction or other non-TB HIV 
related illnesses. 
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